Cargando…
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has received regulatory approval with the indication of cardiorenal protection in patients with chronic kidney disease associated with type 2 diabetes. It is rapidly and completely absorbed and undergoes first-pas...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684710/ https://www.ncbi.nlm.nih.gov/pubmed/37875671 http://dx.doi.org/10.1007/s40262-023-01312-9 |